Acneiform Eruption due to Cetuximab Therapy: A Case Report

dc.contributor.authorArican, Ozer
dc.contributor.authorOnver, Nese
dc.date.accessioned2024-06-12T10:56:07Z
dc.date.available2024-06-12T10:56:07Z
dc.date.issued2011
dc.departmentTrakya Üniversitesien_US
dc.description.abstractCetuximab is a new monoclonal antibody against the epidermal growth factor receptor (EGFR). It has been shown that it is effective against multiple malignancies, including metastatic colorectal carcinoma. EGFR-inhibitors often cause mucocutaneous side effects, most commonly acneiform eruption. Acneiform eruption usually appears suddenly within the first two weeks of the treatment. The incidence and degree of eruption positively correlate with increasing doses and duration of the treatment with EGFR-inhibitors. Here, we report a case of severe acneiform eruption due to cetuximab in a 50-year-old female patient with colorectal cancer with multiple pulmonary and liver metastases.en_US
dc.identifier.doi10.5152/tdd.2011.06
dc.identifier.endpage32en_US
dc.identifier.issn1307-7635
dc.identifier.issn1308-5255
dc.identifier.issue1en_US
dc.identifier.scopus2-s2.0-79955592325en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage29en_US
dc.identifier.urihttps://doi.org/10.5152/tdd.2011.06
dc.identifier.urihttps://hdl.handle.net/20.500.14551/19681
dc.identifier.volume5en_US
dc.identifier.wosWOS:000420868700007en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.language.isotren_US
dc.publisherGalenos Yayinciliken_US
dc.relation.ispartofTurk Dermatoloji Dergisi-Turkish Journal Of Dermatologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCetuximaben_US
dc.subjectAcneiform Eruptionen_US
dc.subjectAdverse Effecten_US
dc.subjectTherapyen_US
dc.titleAcneiform Eruption due to Cetuximab Therapy: A Case Reporten_US
dc.typeArticleen_US

Dosyalar